A Phase 4 interventional study of Carbetocin and Carbetocin in Uterine Atony and Post-partum Hemorrhage, sponsored by Laval University. Completed at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-29.
Sponsored by Laval University · Phase 4, Interventional, and Treatment
The purpose of this study is to evaluate the effectiveness of two doses of carbetocin (50 mcg vs 100 mcg) in preventing uterine atony during elective cesarean section.
Postpartum hemorrhage is a major cause of mortality and morbidity in the world, and it is most often caused by uterine atony. To prevent this complication, uterotonic medication is used during elective cesarean section.
Carbetocin, a long-acting synthetic analogue of oxytocin, has been used for this purpose for many years. This medication has numerous side effects: hypotension, tachycardia, nausea, vomiting, chest pain, etc. Using a smaller dose of carbetocin might lower the incidence of these side effects, without compromising prevention of uterine atony in a low-risk group of patient.
445 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.
This study's enrollment of 72 is below the median of 148 across 340 interventional studies indexed under Postpartum Hemorrhage.
Browse Postpartum Hemorrhage studies →Laval University is the lead sponsor of 371 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Carbetocin
Drug: Carbetocin
Administration of carbetocin 50 mcg , after clamping the umbilical cord
Administration of carbetocin 100 mcg , after clamping the umbilical cord
Utilization of a second uterotonic drug
Time frame: First 48 hours of the postpartum
Incidence of side effects
Time frame: During the fifteen minutes following the administration of carbetocin
Incidence of major complications
Time frame: First 48 hours of the postpartum
Drop in hemoglobin measurement
Time frame: on the second post-partum day
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laval University